2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.Post author:alarpharmPost published:13 . 5 . 2022Post category:Media releases You Might Also Like 2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual Property Administration, Application No. 201780055635.3 21 . 11 . 2022 2024/02/19 ALA-3000 has received a notice of allowance from Mexican Institute of Industrial Property (IMPI) after examination. (Patent Application No. 2021006029) 29 . 2 . 2024 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 9 . 5 . 2022 2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021
2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual Property Administration, Application No. 201780055635.3 21 . 11 . 2022
2024/02/19 ALA-3000 has received a notice of allowance from Mexican Institute of Industrial Property (IMPI) after examination. (Patent Application No. 2021006029) 29 . 2 . 2024
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 9 . 5 . 2022
2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021